Monitoring to the Evolution of Motor Function in SMA Type II Adults Patients Treated With SPINRAZA®
study id #: NCT04159987
condition: Spinal Muscular Atrophy
status: Not yet recruiting
purpose:SPINRAZA® (Nusinersen) is the first intrathecal administered drug which was approved by the FDA to treat SMA children and adults (2016). The aim is to monitor the evolution of the Motor Function Measure-32 for SMA type II adult patients treated with SPINRAZA® (Nusinersen).
intervention: Spinraza intrathecal injection
results: https://clinicaltrials.gov/ct2/show/results/NCT04159987
last updated: February 04, 2022
-
New Treatment Can Help Fresno Infant With Rare Genetic DisorderA Fresno family is holding onto hope aft...
-
Stanford Healthcare – Spinal Muscular AtrophyStanford Neuromuscular Program has exten...
-
How One Mother Is Raising Awareness for Spinal Muscular Atrophy – A Leading Genetic Cause of Infant DeathWhen Nicole Clark’s son Brady was born...
-
Identification of Specific Gene Methylation Patterns During Motor Neuron Differentiation From Spinal Muscular Atroph...Spinal muscular atrophy is a progressive...
-
Screening of Neonatal UK Dried Blood Spots Using a Duplex SMN1 Screening AssaySpinal muscular atrophy (SMA) is an auto...
-
Carrier Screening for Genetic ConditionsCarrier screening is a term used to desc...
-
Generation of DMBi002-A Human Induced Pluripotent Stem Cell Line From Patient With Spinal Muscular Atrophy Type 3Spinal Muscular Atrophy (SMA) is a genet...